P. Mukhopadhyay

发表

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.

R. Suresh, Pabak Mukhopadhyay, E. Veltri, 2003, The American journal of cardiology.

Bayesian analysis of zero-inflated regression models

Jye-Chyi Lu, Sujit K. Ghosh, S. Ghosh, 2006 .

Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial

P. Kwo, D. Bernstein, D. Pound, 2007, Hepatology.

Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer

M. Piccart, G. Hortobagyi, J. Baselga, 2012 .

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

E. Schiff, T. Berg, J. Bruix, 2009, Gastroenterology.

988 SUSTAINED VIRAL RESPONSE (SVR) IS DEPENDENT ON BASELINE CHARACTERISTICS IN THE RETREATMENT OF PREVIOUS ALFA INTERFERON/RIBAVIRIN (I/R) NONRESPONDERS (NR): FINAL RESULTS FROM THE EPIC3 PROGRAM

E. Schiff, T. Berg, J. Albrecht, 2008 .

Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).

C. Isaacs, Bing-he Xu, F. André, 2013 .

Immunogenicity, Safety and Efficacy Comparison of Wockhardt’s Biosimilar Insulin Glargine—Glaritus® with Reference Product— Lantus®: Study Protocol & Early Data Trends

P. Khosla, R. Jain, P. Mukhopadhyay, 2018 .

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

G. Caponigro, S. Scherer, C. Germa, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Six Months Comparative Evaluation of Efficacy and Safety of Wockhardt's Biosimilar Insulin Glargine (Glaritus®) with Reference Insulin Glargine (Lantus®) in Type 2 Diabetes Mellitus in India: Results of Interim Analysis

S. Sharma, P. Khosla, R. Jain, 2020, Advances in Diabetes and Metabolism.

Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

F. André, M. Campone, F. Dalenc, 2010 .

5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab

J. Bergh, F. Cardoso, A. Fasolo, 2009 .

S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.

M. Piccart, G. Hortobagyi, J. Baselga, 2011 .

Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine.

E. Perez, G. Hortobagyi, L. Bosserman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC

E. Schiff, J. Albrecht, P. Kwo, 2008 .

991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY

William M. Lee, E. Schiff, J. Albrecht, 2008 .

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

William M. Lee, E. Schiff, J. Albrecht, 2009, The New England journal of medicine.

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.

F. André, M. Campone, J. Soria, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

M. Piccart, G. Hortobagyi, J. Baselga, 2012, The New England journal of medicine.

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.

R. Suresh, R. Mills, E. Veltri, 2003, European heart journal.

Bayesian Analysis of Quality Adjusted Lifetime (QAL) Data

P. Mukhopadhyay, Sujit Ghosh, 2007 .

A Quality-Adjusted Survival (Q-TWiST) Model for Evaluating Treatments for Advanced Stage Cancer

R. Gelber, S. Gelber, B. Cole, 2004, Journal of biopharmaceutical statistics.

BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).

M. Buyse, F. André, H. Burris, 2012 .

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.

S. Peters, N. Rizvi, V. Papadimitrakopoulou, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Use of Adaptive Design in Late-Stage Oncology Trials

Satrajit Roychoudhury, P. Mukhopadhyay, A. Chakravartty, 2018, Statistical Approaches in Oncology Clinical Development.